Oryzon Genomics SA's total assets for Q1 2026 were €141.70M, a decrease of -1.95% from the previous quarter. MX:ORYN total liabilities were €23.41M for the fiscal quarter, a -12.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.